Table 3.

Drug-related treatment-emergent adverse events in the atorvastatin study

Adverse event	No. (%) of subjectsb
	SD ATO (n = 10)	MD BOC (n = 10)	MD BOC, SD ATO (n = 10)	Total (n = 10)
Any drug-relateda adverse event	1 (10)	5 (50)	0	5 (50)
Gastrointestinal disorders	0	5 (50)	0	5 (50)
Abdominal discomfort	0	1 (10)	0	1 (10)
Abdominal distension	0	1 (10)	0	1 (10)
Constipation	0	3 (30)	0	3 (30)
Diarrhea	0	1 (10)	0	1 (10)
Flatulence	0	1 (10)	0	1 (10)
Gastroesophageal reflux disease	0	1 (10)	0	1 (10)
Nervous system disorders	1 (10)	3 (30)	0	4 (40)
Dizziness	0	1 (10)	0	1 (10)
Dysgeusia	0	3 (30)	0	3 (30)
Headache	1 (10)	0	0	1 (10)
Respiratory, thoracic, mediaspinal disorders	0	1 (10)	0	1 (10)
Cough	0	1 (10)	0	1 (10)

^aPossibly or probably drug related.

^bATO, atorvastatin; BOC, boceprevir; MD, multiple dose; SD, single dose.